Furthermore, they found that miR-223 inhibition downregulated the GBM progression genes which were repressed by PAX6 (such as the metalloproteinases MMP2 and MMP9 and vascular endothelial growth factor VEGFA). The gene discussed is PAX6; the disease is glioblastoma.